AstraZeneca plc (AZN) Stock Rating Reaffirmed by J P Morgan Chase & Co
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by research analysts at J P Morgan Chase & Co in a report issued on Thursday. They presently have a GBX 4,500 ($58.12) price target on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price target suggests a potential downside of 4.65% from the company’s previous close.
AZN has been the topic of several other reports. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, June 21st. Deutsche Bank AG decreased their price target on shares of AstraZeneca plc from GBX 5,700 ($73.61) to GBX 5,300 ($68.45) and set a “buy” rating on the stock in a report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a report on Tuesday, August 8th. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a report on Monday, June 5th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a GBX 5,000 ($64.57) price target on shares of AstraZeneca plc in a report on Monday, June 19th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of GBX 5,022.91 ($64.87).
Shares of AstraZeneca plc (LON AZN) traded down 1.80% during trading on Thursday, hitting GBX 4719.50. 3,225,455 shares of the stock were exchanged. The firm has a 50 day moving average price of GBX 4,556.15 and a 200 day moving average price of GBX 4,880.61. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The firm’s market capitalization is GBX 59.75 billion.
In related news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.